cerdulatinib
Small moleculeexperimental
Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01994382)
Timeline
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1- Mol. weight
- 445.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCerdulatinib ↗
- ChEMBLCHEMBL4116008 ↗
- ChEMBLCHEMBL3545284 ↗
Also known as
- 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
- cerdulatinib
- cerdulatinib
- cerdulatinib
- cerdulatinib
- prt062070
- prt-062070
- prt-062070
- prt-2070
- prt-2070
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04103060 | Phase 2 | Sep 30, 2019 | Roivant Sciences, Inc. |
| NCT04021082 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2019 | Portola Pharmaceuticals |
| NCT01994382 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | Portola Pharmaceuticals |
| NCT04757259 | N/A | — | Alexion |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Portola Pharmaceuticals | For profit | 2 | 2 | 2 | 2013 |
| Alexion | For profit | 1 | 1 | 1 | — |
| Roivant Sciences, Inc. | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1